Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Camm AJ., Kirchhof P., Lip GYH., Schotten U., Savelieva I., Ernst S., Van Gelder IC., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., De Caterina R., De Sutter J., Goette A., Gorenek B., Heldal M., Hohloser SH., Kolh P., Le Heuzey J-Y., Ponikowski P., Rutten FH., ESC Committee for Practice Guidelines None.

Original publication

DOI

10.1093/europace/euq350

Type

Journal article

Journal

Europace

Publication Date

10/2010

Volume

12

Pages

1360 - 1420

Keywords

Acute Coronary Syndrome, Aged, Angiotensin-Converting Enzyme Inhibitors, Anti-Arrhythmia Agents, Anticoagulants, Athletes, Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Comorbidity, Diabetes Mellitus, Electric Countershock, Female, Fibrinolytic Agents, Heart Failure, Heart Rate, Heart Valve Diseases, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperthyroidism, Lung Diseases, Male, Middle Aged, Mineralocorticoid Receptor Antagonists, Platelet Aggregation Inhibitors, Pregnancy, Prevalence, Wolff-Parkinson-White Syndrome